Signaling mechanisms regulating B-lymphocyte activation and tolerance

Journal of Molecular Medicine

Volumn 93, Issue 2, 2015, Pages 143-158

  Hobeika, Elias ^a,b   Nielsen, Peter J ^a,b   Medgyesi, David ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

Autoimmunity; B lymphocyte; B cell tolerance; Inhibitory signaling

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; B LYMPHOCYTE ANTIGEN; CALCIUM; CD19 ANTIGEN; CD40 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; IMMUNOGLOBULIN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ACTIN FILAMENT; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; AUTOIMMUNE DISEASES; B LYMPHOCYTE; DRUG EFFECTS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84922432086     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-015-1252-8     Document Type: Review

References (176)

1. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC (2003) Predominant autoantibody production by early human B cell precursors. Science 301:1374–1377
2. Thomas A Packard JCC (2013) B lymphocyte antigen receptor signaling: initiation, amplification, and regulation. F1000Prime Reports. doi: 10.12703/P5-40
3. Stepanek O, Draber P, Drobek A, Horejsi V, Brdicka T (2013) Nonredundant roles of Src-family kinases and Syk in the initiation of B-cell antigen receptor signaling. J Immunol 190:1807–1818
4. Mukherjee S, Zhu J, Zikherman J, Parameswaran R, Kadlecek TA, Wang Q, Au-Yeung B, Ploegh H, Kuriyan J, Das J (2013) Monovalent and multivalent ligation of the B cell receptor exhibit differential dependence upon Syk and Src family kinases. Sci Signal. doi:10.1126/scisignal.2003220
5. Okada T, Maeda A, Iwamatsu A, Gotoh K, Kurosaki T (2000) BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 13:817–827
6. Jumaa H, Hendriks RW, Reth M (2005) B cell signaling and tumorigenesis. Annu Rev Immunol 23:415–445
7. Engels N, Wollscheid B, Wienands J (2001) Association of SLP-65/BLNK with the B cell antigen receptor through a non-ITAM tyrosine of Ig-α. Eur J Immunol 31:2126–2134
8. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik J-H, DePinho RA, Kutok JL, Kearney JF, Otipoby KL, Rajewsky K (2009) PI3 kinase signals BCR-dependent mature B cell survival. Cell 139:573–586
9. Oh-hora M, Rao A (2008) Calcium signaling in lymphocytes. Curr Opin Immunol 20:250–258
10. Maus M, Medgyesi D, Kiss E, Schneider AE, Enyedi A, Szilágyi N, Matkó J, Sármay G (2013) B cell receptor-induced Ca2+ mobilization mediates F-actin rearrangements and is indispensable for adhesion and spreading of B lymphocytes. J Leukoc Biol 93:537–547
11. Blachly JS, Baiocchi RA (2014) Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol 167:19–32
12. Dieterle AM, Böhler P, Keppeler H, Alers S, Berleth N, Drießen S, Hieke N, Pietkiewicz S, Löffler AS, Peter C et al (2014) PDK1 controls upstream PI3K expression and PIP3 generation. Oncogene 33:3043–3053
13. Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14:219–232
14. Limnander A, Weiss A (2011) Ca-dependent Ras/Erk signaling mediates negative selection of autoreactive B cells. Small GTPases 2:282–288
15. Genot E, Cantrell DA (2000) Ras regulation and function in lymphocytes. Curr Opin Immunol 12:289–294
16. Oh-hora M, Johmura S, Hashimoto A, Hikida M, Kurosaki T (2003) Requirement for Ras guanine nucleotide releasing protein 3 in coupling phospholipase C-gamma2 to Ras in B cell receptor signaling. J Exp Med 198:1841–1851
17. Roose JP, Mollenauer M, Ho M, Kurosaki T, Weiss A (2007) Unusual interplay of two types of Ras activators, RasGRP and SOS, establishes sensitive and robust Ras activation in lymphocytes. Mol Cell Biol 27:2732–2745
18. Ackermann JA, Radtke D, Maurberger A, Winkler TH, Nitschke L (2011) Grb2 regulates B-cell maturation, B-cell memory responses and inhibits B-cell Ca2+ signalling. EMBO J 30:1621–1633
19. Engels N, König LM, Heemann C, Lutz J, Tsubata T, Griep S, Schrader V, Wienands J (2009) Recruitment of the cytoplasmic adaptor Grb2 to surface IgG and IgE provides antigen receptor-intrinsic costimulation to class-switched B cells. Nat Immunol 10:1018–1025
20. Han A, Saijo K, Mecklenbräuker I, Tarakhovsky A, Nussenzweig MC (2003) Bam32 links the B cell receptor to ERK and JNK and mediates B cell proliferation but not survival. Immunity 19:621–632
21. Okamoto T (2006) NF-kappaB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets 6:359–372
22. Sun S-C, Chang J-H, Jin J (2013) Regulation of nuclear factor-κB in autoimmunity. Trends Immunol 34:282–289
23. Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725–734
24. Thome M, Charton JE, Pelzer C, Hailfinger S (2010) Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol 2:a003004
25. Inabe K, Kurosaki T (2002) Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood 99:584–589
26. Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, Tedder TF (2000) CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13:47–57
27. Aiba Y, Kameyama M, Yamazaki T, Tedder TF, Kurosaki T (2008) Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood 111:1497–1503
28. Ingham RJ, Santos L, Dang-Lawson M, Holgado-Madruga M, Dudek P, Maroun CR, Wong AJ, Matsuuchi L, Gold MR (2001) The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase. J Biol Chem 276:12257–12265
29. Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H (1994) The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1:167–178
30. Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Flavell RA (1994) Mice deficient for the CD40 ligand. Immunity 1:423–431
31. Arpin C, Dechanet J, Van Kooten C, Merville P, Grouard G, Briere F, Banchereau J, Liu Y (1995) Generation of memory B cells and plasma cells in vitro. Science 268:720–722
32. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192:1453–1466
33. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293:2111–2114
34. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C et al (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108–2111
35. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A (2000) Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10:785–788
36. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M (2004) TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 173:2245–2252
37. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229:152–172
38. Rickert RC, Jellusova J, Miletic AV (2011) Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 244:115–133
39. Zarnegar B, He JQ, Oganesyan G, Hoffmann A, Baltimore D, Cheng G (2004) Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci U S A 101:8108–8113
40. Claudio E, Brown K, Park S, Wang H, Siebenlist U (2002) BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3:958–965
41. Xie P, Hostager BS, Munroe ME, Moore CR, Bishop GA (2006) Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling. J Immunol 176:5388–5400
42. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J-I, Chen ZJ (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:346–351
43. Liao G, Liao G, Zhang M, Zhang M, Harhaj EW, Harhaj EW, Sun S-C, Sun S-C (2004) Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 279:26243–26250
44. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV (1995) The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83:1243–1252
45. Li X, Yang Y, Ashwell JD (2002) TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416:345–347
46. Zheng C, Kabaleeswaran V, Wang Y, Cheng G, Wu H (2010) Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell 38:101–113
47. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD (2000) Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288:874–877
48. Bertrand MJM, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30:689–700
49. Blankenship JW, Varfolomeev E, Goncharov T, Fedorova AV, Kirkpatrick DS, Izrael-Tomasevic A, Phu L, Arnott D, Aghajan M, Zobel K et al (2009) Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem J 417:149–160
50. Xiao G, Harhaj EW, Sun SC (2001) NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 7:401–409
51. Morrison MD, Reiley W, Zhang M, Sun S-C (2005) An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappaB signaling pathway. J Biol Chem 280:10018–10024
52. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng P-H, Keats JJ, Wang H, Vignali DAA, Bergsagel PL, Karin M (2008) Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 9:1364–1370
53. Gallagher E, Enzler T, Matsuzawa A, Anzelon-Mills A, Otero D, Holzer R, Janssen E, Gao M, Karin M (2007) Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol 8:57–63
54. Moriguchi T, Kuroyanagi N, Yamaguchi K, Gotoh Y, Irie K, Kano T, Shirakabe K, Muro Y, Shibuya H, Matsumoto K et al (1996) A Novel Kinase Cascade Mediated by Mitogen-activated Protein Kinase Kinase 6 and MKK3. J Biol Chem 271:13675–13679
55. Arcipowski KM, Bishop GA (2012) Roles of the Kinase TAK1 in TRAF6-dependent signaling by CD40 and its oncogenic viral Mimic, LMP1. PLoS ONE 7:e42478
56. Craxton A, Shu G, Graves JD, Saklatvala J, Krebs EG, Clark EA (1998) p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J Immunol 161:3225–3236
57. Badr G, Borhis G, Lefevre EA, Chaoul N, Deshayes F, Dessirier V, Lapree G, Tsapis A, Richard Y (2008) BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 111:2744–2754
58. Arron JR, Vologodskaia M, Wong BR, Naramura M, Kim N, Gu H, Choi Y (2001) A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J Biol Chem 276:30011–30017
59. Andjelic S, Hsia C, Suzuki H, Kadowaki T, Koyasu S, Liou HC (2000) Phosphatidylinositol 3-Kinase and NF- B/Rel Are at the divergence of CD40-mediated proliferation and survival pathways. J Immunol 165:3860–3867
60. Jellusova J, Miletic AV, Cato MH, Lin W-W, Hu Y, Bishop GA, Shlomchik MJ, Rickert RC (2013) Context-specific BAFF-R signaling by the NF-κB and PI3K pathways. Cell Rep 5:1022–1035
61. Browne EP (2012) Regulation of B-cell responses by Toll-like receptors. Immunology 136:370–379
62. Meyer-Bahlburg A, Rawlings DJ (2008) B cell autonomous TLR signaling and autoimmunity. Autoimmun Rev 7:313–316
63. Green NM, Marshak-Rothstein A (2011) Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol 23:106–112
64. Liu Y, Yin H, Zhao M, Lu Q (2013) TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8402-y
65. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O, Akira S (2008) Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 9:684–691
66. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT (2005) The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 280:17005–17012
67. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S-I, Honda K, Ohba Y, Mak TW et al (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:243–249
68. Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, Shinohara M, Takayanagi H, Ohba Y, Taniguchi T, Honda K (2006) Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. Proc Natl Acad Sci U S A 103:15136–15141
69. Nishizumi H, Horikawa K, Mlinaric-Rascan I, Yamamoto T (1998) A double-edged kinase Lyn: a positive and negative regulator for antigen receptor-mediated signals. J Exp Med 187:1343–1348
70. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, Stacker SA, Dunn AR (1995) Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83:301–311
71. Hua Z, Gross AJ, Lamagna C, Ramos-Hernández N, Scapini P, Ji M, Shao H, Lowell CA, Hou B, DeFranco AL (2014) Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol 192:875–885
72. Tsubata T (2012) Role of inhibitory BCR co-receptors in immunity. Infect Disord Drug Targets 12:181–190
73. Pao LI, Badour K, Siminovitch KA, Neel BG (2007) Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol 25:473–523
74. Pao LI, Lam K-P, Henderson JM, Kutok JL, Alimzhanov M, Nitschke L, Thomas ML, Neel BG, Rajewsky K (2007) B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27:35–48
75. Huck S, Le Corre R, Youinou P, Zouali M (2001) Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 33:213–224
76. Miyagawa H, Yamai M, Sakaguchi D, Kiyohara C, Tsukamoto H, Kimoto Y, Nakamura T, Lee JH, Tsai C-Y, Chiang B-L et al (2008) Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus. Rheumatology (Oxford) 47:158–164
77. Croker BA, Lawson BR, Rutschmann S, Berger M, Eidenschenk C, Blasius AL, Moresco EMY, Sovath S, Cengia L, Shultz LD et al (2008) Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci U S A 105:15028–15033
78. An H, Hou J, Zhou J, Zhao W, Xu H, Zheng Y, Yu Y, Liu S, Cao X (2008) Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 9:542–550
79. Kubo T, Uchida Y, Watanabe Y, Abe M, Nakamura A, Ono M, Akira S, Takai T (2009) Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med 206:1971–1982
80. Nakano-Yokomizo T, Tahara-Hanaoka S, Nakahashi-Oda C, Nabekura T, Tchao NK, Kadosaki M, Totsuka N, Kurita N, Nakamagoe K, Tamaoka A et al (2011) The immunoreceptor adapter protein DAP12 suppresses B lymphocyte-driven adaptive immune responses. J Exp Med. doi:10.1084/jem.20101623
81. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 98:13866–13871
82. Koncz G, Tóth GK, Bökönyi G, Kéri G, Pecht I, Medgyesi D, Gergely J, Sármay G (2001) Co-clustering of Fcgamma and B cell receptors induces dephosphorylation of the Grb2-associated binder 1 docking protein. Eur J Biochem 268:3898–3906
83. Arechiga AF, Habib T, He Y, Zhang X, Zhang Z-Y, Funk A, Buckner JH (2009) Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 182:3343–3347
84. Dai X, James RG, Habib T, Singh S, Jackson S, Khim S, Moon RT, Liggitt D, Wolf-Yadlin A, Buckner JH et al (2013) A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest 123:2024–2036
85. Wang X, Li J-P, Kuo H-K, Chiu L-L, Dement GA, Lan J-L, Chen D-Y, Yang C-Y, Hu H, Tan T-H (2012) Down-regulation of B cell receptor signaling by hematopoietic progenitor kinase 1 (HPK1)-mediated phosphorylation and ubiquitination of activated B cell linker protein (BLNK). J Biol Chem 287:11037–11048
86. Helgason CD, Kalberer CP, Damen JE, Chappel SM, Pineault N, Krystal G, Humphries RK (2000) A dual role for Src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: aberrant development and enhanced function of b lymphocytes in ship -/- mice. J Exp Med 191:781–794
87. Brauweiler A, Tamir I, Dal Porto J, Benschop RJ, Helgason CD, Humphries RK, Freed JH, Cambier JC (2000) Differential regulation of B cell development, activation, and death by the Src homology 2 domain-containing 5′ inositol phosphatase (Ship). J Exp Med 191:1545–1554
88. O’Neill SK, Getahun A, Gauld SB, Merrell KT, Tamir I, Smith MJ, Dal Porto JM, Li Q-Z, Cambier JC (2011) Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. Immunity 35:746–756
89. Leung W-H, Tarasenko T, Biesova Z, Kole H, Walsh ER, Bolland S (2013) Aberrant antibody affinity selection in SHIP-deficient B cells. Eur J Immunol 43:371–381
90. Ono M, Bolland S, Tempst P, Ravetch JV (1996) Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383:263–266
91. Bolland S, Pearse RN, Kurosaki T, Ravetch JV (1998) SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 8:509–516
92. Carver DJ, Aman MJ, Ravichandran KS (2000) SHIP inhibits Akt activation in B cells through regulation of Akt membrane localization. Blood 96:1449–1456
93. Tamir I, Stolpa JC, Helgason CD, Nakamura K, Bruhns P, Daëron M, Cambier JC (2000) The RasGAP-binding protein p62dok is a mediator of inhibitory FcgammaRIIB signals in B cells. Immunity 12:347–358
94. Maxwell MJ, Duan M, Armes JE, Anderson GP, Tarlinton DM, Hibbs ML (2011) Genetic segregation of inflammatory lung disease and autoimmune disease severity in SHIP-1-/- mice. J Immunol 186:7164–7175
95. Crowley JE, Stadanlick JE, Cambier JC, Cancro MP (2009) FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation. Blood 113:1464–1473
96. Brauweiler A, Tamir I, Marschner S, Helgason CD, Cambier JC (2001) Partially distinct molecular mechanisms mediate inhibitory FcgammaRIIB signaling in resting and activated B cells. J Immunol 167:204–211
97. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK (1997) P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 94:9052–9057
98. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375–13378
99. Anzelon AN, Wu H, Rickert RC (2003) Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol 4:287–294
100. Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA, Sasaki T, Mak TW, Nakano T (2003) Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 197:657–667
101. Cheng S, Hsia CY, Feng B, Liou M-L, Fang X, Pandolfi PP, Liou H-C (2009) BCR-mediated apoptosis associated with negative selection of immature B cells is selectively dependent on Pten. Cell Res 19:196–207
102. Brown KS, Blair D, Reid SD, Nicholson EK, Harnett MM (2004) FcγRIIb-mediated negative regulation of BCR signalling is associated with the recruitment of the MAPkinase-phosphatase, Pac-1, and the 3′-inositol phosphatase, PTEN. Cell Signal 16:71–80
103. Yamanashi Y, Tamura T, Kanamori T, Yamane H, Nariuchi H, Yamamoto T, Baltimore D (2000) Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling. Genes Dev 14:11–16
104. Lemay S, Davidson D, Latour S, Veillette A (2000) Dok-3, a novel adapter molecule involved in the negative regulation of immunoreceptor signaling. Mol Cell Biol 20:2743–2754
105. Stork B, Neumann K, Goldbeck I, Alers S, Kähne T, Naumann M, Engelke M, Wienands J (2007) Subcellular localization of Grb2 by the adaptor protein Dok-3 restricts the intensity of Ca2+ signaling in B cells. EMBO J 26:1140–1149
106. Lösing M, Goldbeck I, Manno B, Oellerich T, Schnyder T, Bohnenberger H, Stork B, Urlaub H, Batista FD, Wienands J et al (2013) The Dok-3/Grb2 protein signal module attenuates Lyn kinase-dependent activation of Syk kinase in B cell antigen receptor microclusters. J Biol Chem 288:2303–2313
107. Ng C-H, Xu S, Lam K-P (2007) Dok-3 plays a nonredundant role in negative regulation of B-cell activation. Blood 110:259–266
108. Aiba Y, Yamazaki T, Okada T, Gotoh K, Sanjo H, Ogata M, Kurosaki T (2006) BANK negatively regulates Akt activation and subsequent B cell responses. Immunity 24:259–268
109. Kozyrev SV, Abelson A-K, Wojcik J, Zaghlool A, Linga Reddy MVP, Sanchez E, Gunnarsson I, Svenungsson E, Sturfelt G, Jönsen A et al (2008) Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 40:211–216
110. Dieudé P, Wipff J, Guedj M, Ruiz B, Melchers I, Hachulla E, Riemekasten G, Diot E, Hunzelmann N, Sibilia J et al (2009) BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum 60:3447–3454
111. Medgyesi D, Hobeika E, Biesen R, Kollert F, Taddeo A, Voll RE, Hiepe F, Reth M (2014) The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity. J Exp Med 211:427–440
112. McAlees JW, Sanders VM (2009) Hematopoietic protein tyrosine phosphatase mediates beta2-adrenergic receptor-induced regulation of p38 mitogen-activated protein kinase in B lymphocytes. Mol Cell Biol 29:675–686
113. Davidson D, Veillette A (2001) PTP-PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates. EMBO J 20:3414–3426
114. Qian Y, Qin J, Cui G, Naramura M, Snow EC, Ware CF, Fairchild RL, Omori SA, Rickert RC, Scott M et al (2004) Act1, a negative regulator in CD40- and BAFF-mediated B cell survival. Immunity 21:575–587
115. Qian Y, Schiemann B, Giltiay N, Gommerman JL, Xiao J, Vora K, Wang Y, Cachero TG, Tian J, Shulga-Morskaya S et al (2008) Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjögren’s syndrome. Eur J Immunol 38:2219–2228
116. Hüffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, Juneblad K, Apel M, McManus R, Ho P et al (2010) Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 42:996–999
117. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, Spencer CCA, Knight J, Weale ME, Allen MH, Barton A, Band G, Bellenguez C (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42:985–990
118. Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, Belouchi M, Fournier H, Reinhard C, Ding J et al (2010) Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 42:991–995
119. Perricone C, Ciccacci C, Ceccarelli F, Di Fusco D, Spinelli FR, Cipriano E, Novelli G, Valesini G, Conti F, Borgiani P (2013) TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. Immunogenetics 65:703–709
120. Buchta CM, Bishop GA (2014) TRAF5 negatively regulates TLR signaling in B lymphocytes. J Immunol 192:145–150
121. Brummelkamp TR, Nijman SMB, Dirac AMG, Bernards R (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424:797–801
122. Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D, Courtois G (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424:801–805
123. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424:793–796
124. Yoshida H, Jono H, Kai H, Li J-D (2005) The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 280:41111–41121
125. Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, Derry JMJ, Jain A (2006) Impaired regulation of NF-κB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 116:3042–3049
126. Jin W, Reiley WR, Lee AJ, Wright A, Wu X, Zhang M, Sun S-C (2007) Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J Biol Chem 282:15884–15893
127. Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL et al (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430:694–699
128. Shembade N, Ma A, Harhaj EW (2010) Inhibition of NF- B signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327:1135–1139
129. Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L, Barrera J, Lowell CA, Utz PJ, Malynn BA et al (2010) The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 33:181–191
130. Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wójtowicz E, Soberon V, Schenten D, Mack B, Reutelshöfer M et al (2011) B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 117:2227–2236
131. Hövelmeyer N, Reissig S, Thi Xuan N, Adams-Quack P, Lukas D, Nikolaev A, Schlüter D, Waisman A (2011) A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol 41:595–601
132. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PIW, Maller J, Pe’er I, Burtt NP, Blumenstiel B, DeFelice M et al (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39:1477–1482
133. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, Burtt NP, Guiducci C, Parkin M, Gates C et al (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40:1059–1061
134. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, Petri MA, Kamboh MI, Manzi S et al (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40:1062–1064
135. Hu H, Brittain GC, Chang J-H, Puebla-Osorio N, Jin J, Zal A, Xiao Y, Cheng X, Chang M, Fu Y-X et al (2013) OTUD7B controls non-canonical NF-κB activation through deubiquitination of TRAF3. Nature 494:371–374
136. Liu X, Chen W, Wang Q, Li L, Wang C (2013) Negative regulation of TLR inflammatory signaling by the SUMO-deconjugating enzyme SENP6. PLoS Pathog 9:e1003480
137. Tanaka T, Grusby MJ, Kaisho T (2007) PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 8:584–591
138. Qiao G, Lei M, Li Z, Sun Y, Minto A, Fu Y-X, Ying H, Quigg RJ, Zhang J (2007) Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B. J Immunol 179:4473–4479
139. Rao N (2001) The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. EMBO J 20:7085–7095
140. Sohn HW, Gu H, Pierce SK (2003) Cbl-b negatively regulates B cell antigen receptor signaling in mature B cells through ubiquitination of the tyrosine kinase Syk. J Exp Med 197:1511–1524
141. Kitaura Y, Jang IK, Wang Y, Han Y-C, Inazu T, Cadera EJ, Schlissel M, Hardy RR, Gu H (2007) Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 26:567–578
142. Kawagoe T, Takeuchi O, Takabatake Y, Kato H, Isaka Y, Tsujimura T, Akira S (2009) TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol 10:965–972
143. Jin J, Xiao Y, Chang J-H, Yu J, Hu H, Starr R, Brittain GC, Chang M, Cheng X, Sun S-C (2012) The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-κB signaling. Nat Immunol 13:1101–1109
144. Xie P, Poovassery J, Stunz LL, Smith SM, Schultz ML, Carlin LE, Bishop GA (2011) Enhanced Toll-like receptor (TLR) responses of TNFR-associated factor 3 (TRAF3)-deficient B lymphocytes. J Leukoc Biol 90:1149–1157
145. Troutman TD, Hu W, Fulenchek S, Yamazaki T, Kurosaki T, Bazan JF, Pasare C (2012) Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc Natl Acad Sci U S A 109:273–278
146. Ni M, MacFarlane AW, Toft M, Lowell CA, Campbell KS, Hamerman JA (2012) B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. Proc Natl Acad Sci U S A 109:267–272
147. Recher M, Burns SO, de la Fuente MA, Volpi S, Dahlberg C, Walter JE, Moffitt K, Mathew D, Honke N, Lang PA (2012) B cell–intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood 119:2819–2828
148. Becker-Herman S, Meyer-Bahlburg A, Schwartz MA, Jackson SW, Hudkins KL, Liu C, Sather BD, Khim S, Liggitt D, Song W et al (2011) WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med 208:2033–2042
149. Liu C, Bai X, Wu J, Sharma S, Upadhyaya A, Dahlberg CIM, Westerberg LS, Snapper SB, Zhao X, Song W (2013) N-wasp is essential for the negative regulation of B cell receptor signaling. PLoS Biol 11:e1001704
150. Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40:205–211
151. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673–2677
152. Nakken B, Munthe LA, Konttinen YT, Sandberg AK, Szekanecz Z, Alex P, Szodoray P (2011) B-cells and their targeting in rheumatoid arthritis–current concepts and future perspectives. Autoimmun Rev 11:28–34
153. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A et al (2010) CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115:1204–1213
154. Li Y, Chen F, Putt M, Koo YK, Madaio M, Cambier JC, Cohen PL, Eisenberg RA (2008) B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol 181:2961–2972
155. Hardy IR, Anceriz N, Rousseau F, Seefeldt MB, Hatterer E, Irla M, Buatois V, Chatel LE, Getahun A, Fletcher A et al (2014) Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. J Immunol 192:1641–1650
156. Dörner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5:433–441
157. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA et al (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14:748–755
158. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J et al (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15:781–787
159. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ et al (2012) Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64:493–503
160. Gadina M (2014) Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol 26:237–243
161. Ho L-J, Lai J-H (2014) Small-molecule inhibitors for autoimmune arthritis: success, failure and the future. Eur J Pharmacol. doi:10.1016/j.ejphar.2014.08.031
162. Ball J, Archer S, Ward S (2014) PI3K inhibitors as potential therapeutics for autoimmune disease. Drug Discov Today 19:1195–1199
163. Zheng X, Suzuki M, Zhang X, Ichim TE, Zhu F, Ling H, Shunnar A, Wang MH, Garcia B, Inman RD et al (2010) RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther 12:R13
164. Fairfax K, Mackay IR, Mackay F (2012) BAFF/BLyS inhibitors: a new prospect for treatment of systemic lupus erythematosus. IUBMB Life 64:595–602
165. Connolly DJ, O’Neill LAJ (2012) New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 12:510–518
166. Liossis SN, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis MM, Sfikakis PP (2001) B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med 49:157–165
167. Vang T, Miletic AV, Bottini N, Mustelin T (2007) Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 40:453–461
168. Batliwalla FM, Li W, Ritchlin CT, Xiao X, Brenner M, Laragione T, Shao T, Durham R, Kemshetti S, Schwarz E et al (2005) Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med 11:21–29
169. Zhang Q, Long H, Liao J, Zhao M, Liang G, Wu X, Zhang P, Ding S, Luo S, Lu Q (2011) Inhibited expression of hematopoietic progenitor kinase 1 associated with loss of jumonji domain containing 3 promoter binding contributes to autoimmunity in systemic lupus erythematosus. J Autoimmun 37:180–189
170. Potter C, Eyre S, Cope A, Worthington J, Barton A (2007) Investigation of association between the TRAF family genes and RA susceptibility. Ann Rheum Dis 66:1322–1326
171. Graham JP, Arcipowski KM, Bishop GA (2010) Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev 237:226–248
172. Bergholdt R, Taxvig C, Eising S, Nerup J, Pociot F (2005) CBLB variants in type 1 diabetes and their genetic interaction with CTLA4. J Leukoc Biol 77:579–585
173. Gómez-Martín D, Ibarra-Sánchez M, Romo-Tena J, Cruz-Ruíz J, Esparza-López J, Galindo-Campos M, Díaz-Zamudio M, Alcocer-Varela J (2013) Casitas B lineage lymphoma b is a key regulator of peripheral tolerance in systemic lupus erythematosus. Arthritis Rheum 65:1032–1042
174. Higgs HN, Pollard TD (1999) Regulation of actin polymerization by Arp2/3 complex and WASp/Scar proteins. J Biol Chem 274:32531–32534
175. Schurman SH, Candotti F (2003) Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol 15:446–453
176. Rohatgi R, Ma L, Miki H, Lopez M, Kirchhausen T, Takenawa T, Takenawa T, Kirschner MW (1999) The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell 97:221–231